13F Holdings
中文EN

LUCD Lucid Diagnostics Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1799011 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY23.6%
TTM net income YoY8.9%
TTM EPS YoY—
Revenue 3-yr CAGR53.6%
Net income 3-yr CAGR—

Margins

Gross margin-16.5%
Operating margin-941.7%
Net margin-892.8%
FCF margin-953.3%
EBITDA margin-925.5%

Returns

ROE-305.6%
ROA-119.8%
ROIC (approx.)—
Asset turnover0.13x

Leverage & solvency

Liabilities / assets78.7%
Debt / equity0.00x
Current ratio1.20x
Interest coverage-3,011.88x

Cash quality & payout

Operating cash flow / net income1.06x
Accruals ratio7.4%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.71M$4.35M$2.43M$377,000$500,000
Cost of revenue$6.67M$7.10M—$100.00M$585,000
Gross profit-$1.96M-$2.75M—$377,000$500,000
R&D expense$5.68M$5.99M$7.25M$11.26M$9.30M
SG&A expense$23.87M$20.16M$19.25M$23.97M$21,000
Operating income-$49.64M-$46.05M-$48.48M-$56.25M-$27.42M
Interest expense$22,000$26,000$416,000$8,000$659,000
Pretax income-$58.01M-$45.53M-$52.67M-$56.17M-$28.08M
Income tax$0$0———
Net income-$58.01M-$45.53M-$52.67M-$56.17M-$28.08M
EBITDA-$48.77M-$44.88M-$45.98M-$54.31M-$27.41M
EPS (basic)-0.69-1.05-1.26-1.55-1.51
EPS (diluted)—-1.05-1.26-1.55-1.51
Weighted avg. shares (diluted)—50.52M41.76M36.17M18.60M
Balance sheet
Cash & equivalents$34.70M$22.36M$18.90M$22.47M$53.66M
Receivables$643,000$45,000$45,000$17,000$200,000
Inventory$353,000$341,000$278,000$111,000—
Current assets$37.47M$25.15M$22.07M$24.36M$57.30M
PP&E, net$809,000$1.06M$1.33M$1.59M$971,000
Intangibles$315,000$736,000$1.42M$3.44M—
Total assets$40.45M$30.71M$27.27M$32.51M$59.00M
Current liabilities$28.58M$23.52M$29.38M$8.43M$4.26M
Total liabilities$29.51M$25.32M$29.58M$9.46M$4.26M
Shareholders' equity$10.94M$5.39M-$2.31M$23.05M$54.74M
Shares outstanding131.10M63.07M42.33M40.52M34.92M
Cash flow statement
Operating cash flow-$46.48M-$44.14M-$32.82M-$29.68M-$17.67M
Capital expenditure$197,000$296,000—$3.20M$862,000
Free cash flow-$46.68M-$44.44M—-$32.88M-$18.53M
Investing cash flow-$197,000-$646,000-$221,000-$4.11M-$862,000
Financing cash flow$59.03M$48.25M$29.46M$2.61M$72.08M
Depreciation & amortization$872,000$1.17M$2.50M$1.94M$4,000
Stock-based compensation$4.49M$4.53M$5.76M$13.86M$9.13M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.